DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Dyne Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$15.23+0.98 (+6.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.15 (−7.02%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$519.41M
- EPS, diluted
- -$3.47
- Free cash flow
- -$480.43M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
-$536.96M
Net income
-$519.41M
EPS, diluted
–
Free cash flow
-$480.43M
Reported periodTrailing twelve months